These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8403085)
1. Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences. Sakurai M; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y Chem Pharm Bull (Tokyo); 1993 Aug; 41(8):1369-77. PubMed ID: 8403085 [TBL] [Abstract][Full Text] [Related]
2. Studies of HIV-1 protease inhibitors. II. Incorporation of four types of hydroxyethylene dipeptide isosteres at the scissile site of substrate sequences. Sakurai M; Higashida S; Sugano M; Nishi T; Saito F; Ohata Y; Handa H; Komai T; Yagi R; Nishigaki T Chem Pharm Bull (Tokyo); 1993 Aug; 41(8):1378-86. PubMed ID: 8403086 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition. Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA. Sakurai M; Higashida S; Sugano M; Komai T; Yagi R; Ozawa Y; Handa H; Nishigaki T; Yabe Y Bioorg Med Chem; 1994 Aug; 2(8):807-25. PubMed ID: 7894975 [TBL] [Abstract][Full Text] [Related]
5. Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors. Hui KY; Hermann RB; Manetta JV; Gygi T; Angleton EL FEBS Lett; 1993 Aug; 327(3):355-60. PubMed ID: 8348964 [TBL] [Abstract][Full Text] [Related]
6. Peptide aldehydes as inhibitors of HIV protease. Sarubbi E; Seneci PF; Angelastro MR; Peet NP; Denaro M; Islam K FEBS Lett; 1993 Mar; 319(3):253-6. PubMed ID: 8458418 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites. Ridky TW; Cameron CE; Cameron J; Leis J; Copeland T; Wlodawer A; Weber IT; Harrison RW J Biol Chem; 1996 Mar; 271(9):4709-17. PubMed ID: 8617736 [TBL] [Abstract][Full Text] [Related]
8. Studies of human immunodeficiency virus type 1 (HIV-1) protease inhibitors. III. Structure-activity relationship of HIV-1 protease inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere. Sakurai M; Higashida S; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):534-40. PubMed ID: 8004698 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Dreyer GB; Metcalf BW; Tomaszek TA; Carr TJ; Chandler AC; Hyland L; Fakhoury SA; Magaard VW; Moore ML; Strickler JE Proc Natl Acad Sci U S A; 1989 Dec; 86(24):9752-6. PubMed ID: 2690072 [TBL] [Abstract][Full Text] [Related]
10. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors. Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718 [TBL] [Abstract][Full Text] [Related]
11. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. Hui KY; Carlson WD; Bernatowicz MS; Haber E J Med Chem; 1987 Aug; 30(8):1287-95. PubMed ID: 3302256 [TBL] [Abstract][Full Text] [Related]
13. Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid. Raju B; Deshpande MS Biochem Biophys Res Commun; 1991 Oct; 180(1):187-90. PubMed ID: 1930215 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 protease by oxim derivatives. Komai T; Yagi R; Suzuki-Sunagawa H; Ishikawa Y; Kasuya A; Miyamoto S; Handa H; Nishigaki T Biochem Biophys Res Commun; 1997 Jan; 230(3):557-61. PubMed ID: 9015361 [TBL] [Abstract][Full Text] [Related]
16. In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. Komai T; Yagi R; Suzuki-Sunagawa H; Sakurai M; Higashida S; Sugano M; Handa H; Mohri H; Yasuoka A; Oka S; Yabe Y; Nishigaki T; Kimura S; Shimada K Biol Pharm Bull; 1997 Feb; 20(2):175-80. PubMed ID: 9057982 [TBL] [Abstract][Full Text] [Related]
17. Statine based tripeptides as potent inhibitors of HIV-1 replication. Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D Biochem Biophys Res Commun; 1992 Oct; 188(2):873-8. PubMed ID: 1445328 [TBL] [Abstract][Full Text] [Related]
18. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353 [TBL] [Abstract][Full Text] [Related]
19. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV. Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195 [TBL] [Abstract][Full Text] [Related]